Atypical antipsychotics in the treatment of schizophrenia: Systematic review, meta-regression and evidence-based treatment recommendations

Atypical antipsychotics in the treatment of schizophrenia: Systematic review, meta-regression and evidence-based treatment recommendations

Detaylı Bibliyografya
Asıl Yazarlar:	Geddes, J, Royal, C
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2000

Benzer Materyaller

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
Yazar:: Geddes, J, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Atypical antipsychotics in the treatment of schizophrenia - Reply
Yazar:: Geddes, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Atypical antipsychotics in the treatment of schizophrenia
Yazar:: Swiss Medical Weekly
Baskı/Yayın Bilgisi: (2003-02-01)

Atypical antipsychotics in the treatment of early-onset schizophrenia
Yazar:: Hrdlicka M, ve diğerleri
Baskı/Yayın Bilgisi: (2015-04-01)

A systematic review of atypical antipsychotic drugs in schizophrenia
Yazar:: A-.M. Bagnall, ve diğerleri
Baskı/Yayın Bilgisi: (2003-01-01)

Comparison of systematic and narrative reviews: the example of the atypical antipsychotics.
Yazar:: Cipriani, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

A systematic review of the use of atypical antipsychotics in autism.
Yazar:: Barnard, L, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
Yazar:: Swartz Marvin, ve diğerleri
Baskı/Yayın Bilgisi: (2006-02-01)

New atypical antipsychotics for schizophrenia: iloperidone
Yazar:: Silvio Caccia, ve diğerleri
Baskı/Yayın Bilgisi: (2010-02-01)

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
Yazar:: Maximilian Huhn, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors.
Yazar:: Leucht, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
Yazar:: Leucht, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
Yazar:: O&#39;Day K, ve diğerleri
Baskı/Yayın Bilgisi: (2013-09-01)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
Yazar:: Yi-Lung Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

Generating evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics.
Yazar:: Geddes, J
Baskı/Yayın Bilgisi: (2003)

Atypical antipsychotics (multiple letters)
Yazar:: McKenna, P, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
Yazar:: Zhi-min Yu, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
Yazar:: Ying Jiao Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
Yazar:: I. A. Vilyum, ve diğerleri
Baskı/Yayın Bilgisi: (2018-08-01)

Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis
Yazar:: Leucht, S, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response
Yazar:: Leucht, S, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Yazar:: Leucht, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis
Yazar:: Leucht, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review
Yazar:: Giulio Longo, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review
Yazar:: Toshi A Furukawa, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis
Yazar:: Zina Sherzad Qadir, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Traditional Chinese Medicine Decoction Combined With Antipsychotic for Chronic Schizophrenia Treatment: A Systematic Review and Meta-analysis
Yazar:: Xiao-Jie Shi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Recovery in schizophrenia: the role of antipsychotic treatment
Yazar:: I. Bitter
Baskı/Yayın Bilgisi: (2024-04-01)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
Yazar:: Haishan Wu, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Yazar:: Correll Christoph U, ve diğerleri
Baskı/Yayın Bilgisi: (2008-04-01)

Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis
Yazar:: Shaoli Li, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

EFFECT OF TYPICAL AND ATYPICAL ANTIPSYCHOTICS ON PLASMA PROLACTIN LEVELS IN SCHIZOPHRENIA
Yazar:: Muhammad Sami Bilal, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole
Yazar:: Topolov Mariyan K., ve diğerleri
Baskı/Yayın Bilgisi: (2016-03-01)

Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine
Yazar:: Yong Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Gender differences in cognitive improvements after two months of atypical antipsychotic treatment in first episode schizophrenia
Yazar:: Wanyi Li, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Amantadine in the Treatment of Sexual Inactivity in Schizophrenia Patients Taking Atypical Antipsychotics—The Pilot Case Series Study
Yazar:: Marek Krzystanek, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
Yazar:: Lei Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Yazar:: Smolen Lee J, ve diğerleri
Baskı/Yayın Bilgisi: (2009-04-01)

The effects of antipsychotic drugs on depression level in patients with schizophrenia: clozapine vs. other atypical antipsychotics
Yazar:: Hülya Ertekin, ve diğerleri
Baskı/Yayın Bilgisi: (2016-08-01)

Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine
Yazar:: B. Jorge, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)